tbuckley/cabot-search huggingface dataset:
Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab
Authors: Thibault Mazard, Piyaporn Boonsirikamchai, Michael J Overman, Mohamed A Asran, Haesun Choi, Delise Herron, Cathy Eng, Dipen M Maru, Marc Ychou, Jean-Nicolas Vauthey, Evelyne M Loyer, Scott Kopetz
Journal: Gut (2017)

Objective The purpose was to validate the prognostic value of an early optimal morphological response on CT in patients treated with bevacizumab-containing chemotherapy for unresectable colorectal cancer liver metastases (CLM). It also evaluated the prognostic value of size-based criteria and the association of optimal morphological response with the receipt of bevacizumab. Design 141 patients treated first using bevacizumab and 142 patients from a randomised study evaluating the addition of bevacizumab to oxaliplatin-based chemotherapy were retrospectively analysed. Radiologists evaluated pretreatment and restaging CT scans using morphological response criteria. Responses were also assessed with size-based criteria: Response Evaluation Criteria in Solid Tumors (RECIST), early tumour shrinkage (ETS) and deepness of response (DpR). The ability of each criterion to predict progression-free survival (PFS), overall survival (OS) and postprogression survival (PPS) was determined using a univariate Cox proportional hazards model. Results In both populations, median PFS was significantly longer for patients achieving an optimal morphological response (10.4 vs 6.8 months, p=0.03; and 8.3 vs 4.9 months, p&lt;00001, respectively). Neither RECIST nor ETS responses were associated with a prolonged PFS. Median OS was longer for those with an optimal morphological response but only at second restaging in the first population (n=141, 20.8 vs 12.3 months, p=0.002). DpR but not optimal morphological response was associated with PPS. In the randomised study, an optimal morphological response was 6.2 times more likely among patients receiving bevacizumab (p&lt;0.0001). Conclusion In patients with unresectable CLM, early morphological response may be a better predictor of PFS than size-based response. The addition of bevacizumab improves morphological response rate.
Lysosome signaling controls the migration of dendritic cells
Authors: Marine Bretou, Pablo J. Sáez, Doriane Sanséau, Mathieu Maurin, Danielle Lankar, Melanie Chabaud, Carmine Spampanato, Odile Malbec, Lucie Barbier, Shmuel Muallem, Paolo Maiuri, Andrea Ballabio, Julie Helft, Matthieu Piel, Pablo Vargas, Ana-Maria Lennon-Duménil
Journal: Science Immunology (2017)

Lysosomes control dendritic cell migration by linking macropinocytosis to cytoskeletal rearrangement via the TFEB-TRPML1 axis.
TCT-53 Transapical Off-pump Echo-guided Mitral Valve Repair with Neochordae Implantation: 2-Years Results
Authors: Andrea Colli, Eleonora Bizzotto, Erica Manzan, Laura Besola, Roberto Bellu, Alessandro Fiocco, Nicola Pradegan, Matteo Nadali, Gino Gerosa
Journal: Journal of the American College of Cardiology (2017)
Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation
Authors: Wayne Batchelor, David E. Kandzari, Scott Davis, Luis Tami, John C. Wang, Islam Othman, Osvaldo S. Gigliotti, Amir Haghighat, Sarabjeet Singh, Mario Lopez, Gregory Giugliano, Phillip A. Horwitz, Jaya Chandrasekhar, Paul Underwood, Craig A. Thompson, Roxana Mehran
Journal: JAMA Cardiology (2017)

<h3>Importance</h3> There exist limited outcomes data for women and minorities after contemporary percutaneous coronary intervention (PCI). <h3>Objective</h3> To examine 1-year outcomes in women and minorities vs white men after PCI with everolimus-eluting stents. <h3>Design, Settings, and Participants</h3> The PLATINUM Diversity study was a single-arm study enrolling women and minorities. Patient-level pooling with the PROMUS Element Plus Post-Approval Study was prespecified. Data on social determinants of health and language were collected in the PLATINUM Diversity cohort, which included 1501 patients at 52 US sites. The PROMUS Element Plus Post-Approval study enrolled 2681 patients at 52 US sites with some site overlap and included an "all-comers" population. All patients were enrolled beginning in October 2014 and were followed for 12 months. Analyses began in August 2016. <h3>Interventions</h3> Patients received 1 or more everolimus-eluting stent implantation. <h3>Main Outcomes and Measures</h3> The primary end point was 1-year major adverse cardiac events (MACE), which included death/myocardial infarction (MI)/target vessel revascularization. Secondary ischemic end points were also evaluated. <h3>Results</h3> The pooled study consisted of 4182 patients: 1635 white men (39.1%), 1863 women (white and minority) (44.5%), and 1059 minority patients (women and men) (25.3%). Women and minorities had a higher prevalence of diabetes, prior stroke, hypertension, renal disease, and congestive heart failure than white men but lower rates of multivessel disease, prior coronary artery bypass graft surgery, prior MI, and smoking. Unadjusted 1-year MACE rates (white men, 7.6%; women, 8.6%; minorities, 9.6%) were similar between groups with no significant differences after risk adjustment. The adjusted risk of death/MI was higher among women (odds ratio, 1.6; 95% CI, 1.1-2.4) and minorities (odds ratio, 1.9; 95% CI, 1.2-2.8) compared with white men and the adjusted risk of MI was higher in minorities (odds ratio, 2.6; 95% CI, 1.4-4.8). These differences were driven primarily by nonstent-related MIs. Within the PLATINUM Diversity cohort, the independent predictors of MACE were cardiogenic shock, renal disease, history of peripheral vascular disease, multivessel disease, widowhood, and lack of private insurance. <h3>Conclusions and Relevance</h3> After contemporary everolimus-eluting stent implantation, women and minorities experience a similar risk of 1-year MACE but a higher adjusted risk of recurrent ischemic events primarily because of nonstent-related MIs. Both clinical and angiographic factors and social determinants of health, including widowhood and insurance status, contribute to 1-year MACE among women and minorities.
Patients hospitalisés dans des unités d’isolement pour suspicion de SRAS au cours de l’épidémie de SRAS : l’expérience française
Authors: B Issartel, O Lesens, C Chidiac, Y Mouton, D Christmann, D Peyramond
Journal: Eurosurveillance (2005)

Au cours de l’epidemie de SRAS, et conformement aux recommandations de l’OMS, des tests ont ete realises chez de nombreux patients en France et aucun n’etait atteint de la maladie. En mai 2003, au debut de l’epidemie, une etude retrospective a ete menee pour decrire les patients suspectes d’etre infectes par le SRAS et hospitalises en France. Afin d’evaluer la strategie de depistage, ces patients ont ete compares aux cas de SRAS documentes. Au total, 117 patients ont ete inclus dans l’etude. Seuls 3,4% d’entre eux avaient ete en contact proche avec un patient infecte, mais 73,5% venaient d’une region touchee par l’epidemie. Au moment de leur admission a l’hopital, 67,5% presentaient de la fievre et des symptomes respiratoires, et 49,6% avaient de la fievre et des symptomes non specifiques. Les symptomes cliniques significativement plus frequents chez les patients atteints de SRAS sont de la fievre, des myalgies, des dyspnees, et des nausees ou des vomissements. Les diagnostics les plus courants etaient une fievre presumee virale et une infection des voies respiratoires. Les signes cliniques ne permettent pas de faire la distinction avec un stade precoce de SRAS, confirmant ainsi l'utilite des definitions de cas de l'OMS dans la decision d'isolement, afin d'eviter la transmission de la maladie.
TCT-92 Polyvascular Disease and Risk of Major Cardiovascular Events in Peripheral Artery Disease—Insights from EUCLID
Authors: Antonio Gutierrez, Hillary Mulder, Schuyler Jones, Frank Rockhold, Jeffrey Berger, Juuso Blomster, William Hiatt, Brian Katona, Lars Norgren, Manesh Patel
Journal: Journal of the American College of Cardiology (2017)
TCT-400 Pre-existing Atrial Fibrillation Increases Mortality After Transcatheter Aortic Valve Replacement: A Meta-Analysis
Authors: Saranapoom Klomjit, Wasawat Vutthikraivit, Subhanudh Thavaraputta, Passisd Laoveeravat, Sakolwan Suchartlikitwong, Pakpoom Tantrachoti, Pattara Rattanawong, Mohammad Ansari
Journal: Journal of the American College of Cardiology (2017)
Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes
Authors: Matthew J. Crowley, John W. Williams, Andrzej S. Kosinski, David A. D’Alessio, John B. Buse
Journal: Diabetes Care (2017)

OBJECTIVE To explore prevalent metformin use as a potential moderator of the cardiovascular effects of dipeptidyl peptidase 4 inhibitors (DPP-4i). RESEARCH DESIGN AND METHODS We performed a meta-analysis of the three major cardiovascular outcomes trials examining DPP-4i. We used meta-regression to examine how the cardiovascular effects of DPP-4i differ between prevalent metformin users and baseline nonusers. RESULTS While prevalent metformin users experienced a trend toward improved cardiovascular outcomes with DPP-4i (summary hazard ratio [HR] 0.92 [95% CI 0.84, 1.01]), baseline metformin nonusers showed a trend toward harm (HR 1.10 [95% CI 0.97, 1.26]). The difference in overall DPP-4i effect between metformin user and nonuser subgroups was statistically significant (P = 0.036). CONCLUSIONS Baseline metformin status may have a moderating effect on cardiovascular outcomes with DPP-4i use. This hypothesis-generating analysis suggests there is residual uncertainty as to how DPP-4i affect cardiovascular outcomes, depending on concurrently prescribed medications.
Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
Authors: Liza J McCann, Clarissa A Pilkington, Adam M Huber, Angelo Ravelli, Duncan Appelbe, Jamie J Kirkham, Paula R Williamson, Amita Aggarwal, Lisa Christopher-Stine, Tamas Constantin, Brian M Feldman, Ingrid Lundberg, Sue Maillard, Pernille Mathiesen, Ruth Murphy, Lauren M Pachman, Ann M Reed, Lisa G Rider, Annet van Royen-Kerkof, Ricardo Russo, Stefan Spinty, Lucy R Wedderburn, Michael W Beresford
Journal: Annals of the Rheumatic Diseases (2017)

Objectives This study aimed to develop consensus on an internationally agreed dataset for juvenile dermatomyositis (JDM), designed for clinical use, to enhance collaborative research and allow integration of data between centres. Methods A prototype dataset was developed through a formal process that included analysing items within existing databases of patients with idiopathic inflammatory myopathies. This template was used to aid a structured multistage consensus process. Exploiting Delphi methodology, two web-based questionnaires were distributed to healthcare professionals caring for patients with JDM identified through email distribution lists of international paediatric rheumatology and myositis research groups. A separate questionnaire was sent to parents of children with JDM and patients with JDM, identified through established research networks and patient support groups. The results of these parallel processes informed a face-to-face nominal group consensus meeting of international myositis experts, tasked with defining the content of the dataset. This developed dataset was tested in routine clinical practice before review and finalisation. Results A dataset containing 123 items was formulated with an accompanying glossary. Demographic and diagnostic data are contained within form A collected at baseline visit only, disease activity measures are included within form B collected at every visit and disease damage items within form C collected at baseline and annual visits thereafter. Conclusions Through a robust international process, a consensus dataset for JDM has been formulated that can capture disease activity and damage over time. This dataset can be incorporated into national and international collaborative efforts, including existing clinical research databases.
Safety, tolerability, and pharmacokinetics of l‐ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia
Authors: R. Todd Stravitz, Michelle Gottfried, Valerie Durkalski, Robert J. Fontana, A. James Hanje, David Koch, Bilal Hameed, Daniel Ganger, Ram M. Subramanian, Stan Bukofzer, William R. Ravis, Kristen Clasen, Averell Sherker, Lanna Little, William M. Lee
Journal: Hepatology (2017)

Cerebral edema remains a significant cause of morbidity and mortality in patients with acute liver failure (ALF) and has been linked to elevated blood ammonia levels. l-ornithine phenylacetate (OPA) may decrease ammonia by promoting its renal excretion as phenylacetylglutamine (PAGN), decreasing the risk of cerebral edema. We evaluated the safety, tolerability, and pharmacokinetics of OPA in patients with ALF and acute liver injury (ALI), including those with renal failure. Forty-seven patients with ALI/ALF and ammonia ≥60 μM were enrolled. Patients received OPA in a dose escalation scheme from 3.3 g every 24 hours to 10 g every 24 hours; 15 patients received 20 g every 24 hours throughout the infusion for up to 120 hours. Plasma phenylacetate (PA) concentrations were uniformly below target (<75 μg/mL) in those receiving 3.3 g every 24 hours (median [interquartile range] 5.0 [5.0] μg/mL), and increased to target levels in all but one who received 20 g every 24 hours (150 [100] μg/mL). Plasma [PAGN] increased, and conversion of PA to PAGN became saturated, with increasing OPA dose. Urinary PAGN clearance and creatinine clearance were linearly related (r = 0.831, P < 0.0001). Mean ammonia concentrations based on the area under the curve decreased to a greater extent in patients who received 20 g of OPA every 24 hours compared with those who received the maximal dose of 3.3 or 6.7 g every 24 hours (P = 0.046 and 0.022, respectively). Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication. The only nonserious AEs possibly related to study drug were headache and nausea/vomiting.OPA was well-tolerated in patients with ALI/ALF, and no safety signals were identified. Target [PA] was achieved at infusion rates of 20 g every 24 hours, leading to ammonia excretion in urine as PAGN in proportion to renal function. Randomized, controlled studies of high-dose OPA are needed to determine its use as an ammonia-scavenging agent in patients with ALF. (Hepatology 2018;67:1003-1013).
Choléra dans la région méditerranéenne : une épidémie en Albanie
Authors: D Greco, I Luizzi, A Sallabanda, A Dibra, E Kacarricy, L Shapo
Journal: Eurosurveillance (1995)

Dans les annees 1990, l'epidemie de cholera par Vibrio cholerae 01 El Tor s'est deplacee du Nord du Pakistan jusqu'a la Mediterranee. Des cas sporadiques de cholera ainsi que des foyers epidemiques ont ete rapportes en 1993 dans plusieurs pays de la partie Sud de l'Europe de l'Est. Des cas ont egalement ete notifies en Crimee et en Turquie ; en Grece, seul un cas importe a ete enregistre (1).
TCT-255 Impact of right atrial pressure on fractional flow reserve calculation in the presence of a chronic total occlusion
Authors: Grigoris Karamasis, Shah Mohdnazri, Firas Al-Janabi, Andreas Kalogeropoulos, Rohan Jagathesan, Gerald Clesham, Kare Tang, Paul Kelly, John Davies, Thomas Keeble
Journal: Journal of the American College of Cardiology (2017)
TCT-744 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: The Final Five-Year Results of the Patient-Level Pooled Analysis From TARGET I and TARGET II Trials
Authors: Bo Xu, Changdong Guan, Yuejin Yang, Runlin Gao
Journal: Journal of the American College of Cardiology (2017)
PET Scans With <sup>18</sup>F-Fluorodeoxyglucose to Diagnose Adrenal Tumors—Reply
Authors: David Taïeb, Karel Pacak
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 12440: Global Longitudinal Strain With 2D-Speckle Tracking Predicts Chemotherapy-related Systolic Dysfunction Independenty of Basal Assessment in Patients With Breast Carcinoma
Authors: Federico Guerra, Marco Marchesini, Daniele Contadini, Alessio Menditto, Marco Morelli, Elisa Piccolo, Marco Tagliavento, Nicola Battelli, Rossana Berardi, Stefano Cascinu, Alessandro Capucci
Journal: Circulation (2015)

Introduction: Recent developments in anticancer therapies for breast carcinoma allowed an improvement in patient survival, notwithstanding a parallel increase of cardiovascular morbidity. Systolic dysfunction and heart failure represent a relevant problem in these patients due to insidious onset and the potential irreversible nature of cardiac damage. Therefore, strong and early predictors of chemoteraphy-realted systolic dysfunction are been sought. Hypothesis: To investigate global longitudinal strain (GLS) assessed by 2D-speckle tracking as a potential early marker of systolic dysfunction in chemoteraphy-treated breast cancer patients. Methods: Population include sixty-nine patients, referred to our unit for cardiologic assessment prior to neo-adjuvant or adjuvant chemotherapy for breast cancer. Patients with prior heart failure and atrial fibrillation were excluded. The protocol included a baseline echocolorDoppler and 2D-strain evaluation before the beginning of chemotherapy and subsequent serial controls every 3 months. In patients developing systolic dysfunction, further unscheduled assessment were made at the cardiologist discretion. Results: Nineteen (27.5%) patients were classified as having cardiotoxicity according to CREC and ESMO criteria. ROC curve analysis showed that a 3-month GLS &lt;-16% predicted subsequent development of systolic dysfunction with good sensitivity and specificity (80% and 90% respectively), with a negative predictive value of 92%. Cardiotoxicity occurred in 8 patients at 6 months and in 11 patients within 9 months; among all of those, 84% of patients already showed a GLS &lt;-16% at 3-month, and 100% at 6-month, confirming the early diagnostic potential of GLS. After chemotherapy suspension and introduction of cardioprotective drugs, GLS remained depressed longer than left ventricular ejection fraction (LVEF) over 1-year follow-up. Conclusions: Strain imaging with 2D-speckle tracking allows the identification of patients at high risk of developing systolic dysfunction. An absolute cut-off value of -16% can provide a useful, time-independent clinical tool to improve follow-up management and concentrate resources on high-risk patients.
PS02.18 Characterization of Patients with KRAS-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Community Practice Setting
Authors: L. Zhang, G. Cuyun Carter, J. Beyrer, L. Li, K. Sheffield, C. Muehlenbein, M. Boye, C. Molife, K. Frantz, W. John, S.M. Gadgeel
Journal: Journal of Thoracic Oncology (2017)
TCT-74 What is the Value of a Second Internal Thoracic Arterial Graft on 3-year Outcomes After CABG in Left Main Disease? Insights from the EXCEL trial
Authors: Daniel Thuijs, Gregg Stone, Patrick Serruys, William Brown, Piet Willem Boonstra, Nicolas Noiseux, Ovidiu Dressler, Joseph Sabik, A. Pieter Kappetein
Journal: Journal of the American College of Cardiology (2017)
Pollution is linked to one in six deaths worldwide, study estimates
Authors: Susan Mayor
Journal: BMJ (2017)

Pollution is associated with an estimated nine million deaths a year worldwide, equivalent to one in six of all deaths, a major study using 2015 data on the global burden of disease has estimated.

The study, reported in the Lancet ,1 found that air pollution was the major contributor to these deaths and was associated with 6.5 million deaths in 2015. Water pollution was implicated in 1.8 million deaths, and workplace related pollution was linked to a further 0.8 million.

Most of these deaths were due to non-communicable diseases including heart disease, stroke, lung cancer, and chronic obstructive pulmonary disease (COPD). The …
TCT-51 Impact of anticoagulation therapy on valve hemodynamics and clinical outcomes after bioprosthetic aortic valve replacement: A pooled analysis of the PARTNER2 trials
Authors: Tarun Chakravarty, Yigal Abramowitz, Wen Cheng, Samir Kapadia, Richard Smalling, Wilson Y. Szeto, Rebecca Hahn, Matthew Finn, Howard Herrmann, Dean Kereiakes, Sunghan Yoon, Susheel Kodali, Vinod Thourani, Maria Alu, Thomas McAndrew, Michael Mack, Martin Leon, Raj Makkar
Journal: Journal of the American College of Cardiology (2017)
Correlation of changes in lean muscle weight with outcome in metastatic pancreatic adenocarcinoma (mPDAC) who undergo taxane-based chemotherapy (CT).
Authors: Daniel H. Ahn, Chul Ahn, Veena Nagar, Matthew Farren, Gregory B. Lesinski, Michael V. Knopp, Tanios S. Bekaii-Saab
Journal: Journal of Clinical Oncology (2015)

e15243 Background: mPDAC is associated with a poor prognosis. The mechanisms of carcinogenesis in mPDAC are complex; involve multiple signaling pathways and inflammatory cytokines that may promote cachexia, a major cause of morbidity and mortality in this disease. The purpose of this study is to understand the factors that influence skeletal muscle changes and their effects on clinical outcomes in pts with mPDAC. Methods: Pt and clinical data were obtained from a recently completed prospective clinical trial in mPDAC where all pts received first line taxane-based CT. We examined changes in plasma CRP, a panel of 32 cytokines, wt and skeletal muscle area (SMA) as determined by a validated method using the third lumbar vertebra on computed tomography as a landmark, at baseline and cycle 3. We defined a difference > 6 cm2 in SMA (correlating to 1 kg of muscle wt gain) as significant. Univariate and multivariate Cox regression models were used to determine the association between laboratory, radiographic and clinical findings with progression free survival (PFS) and overall survival (OS). Results: Data from 60 evaluable pts with mPDAC were included. In univariate analysis, pts with meaningful skeletal muscle gain (SMG) had improved OS (p = 0.06). Regardless of clinical response, Cox regression analysis showed OS is positively associated with significant SMG (HR = 0.96; p = 0.003). Univariate and Cox regression analyses showed SMG is positively associated with PFS (HR 0.97; p = 0.01). IFN-a (p = 0.024) and IFN-g (p = 0.001) were significantly associated with wt loss, consistent with published data. IL-12 was also associated (p = 0.037) with wt loss, which is a novel finding. CRP and the remaining cytokines did not show any significant correlation. Conclusions: SMG is associated with improved OS and PFS in pts with mPDAC who receive taxane-based CT regardless of clinical response. Inflammatory cytokines such as IFN-a, IFN-g and IL-12 may serve as surrogate biomarkers in pts at risk for wt loss. SMG, or the reversal of cachexia impacts survival and may impact treatment response and its significance merits further investigation in the treatment of pts and in clinical trials. Clinical trial information: NCT00998322.